Watchlist Price Alert

AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD

2.13

0.11 (5.45%)

At close: Jun 02, 2025, 2:41 PM

5.45% (1D)

Bid	2.12
Market Cap	634.28M
Revenue (ttm)	23.11M
Net Income (ttm)	-167.87M
EPS (ttm)	-0.56
PE Ratio (ttm)	-3.79
Forward PE	-3.59
Analyst	Buy

Ask	2.13
Volume	2,799,087
Avg. Volume (20D)	4,042,020
Open	2.03
Previous Close	2.02
Day's Range	2.03 - 2.15
52-Week Range	1.89 - 4.07
Beta	0.46

About ABCL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ABCL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ABCL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+15.94%

Shares of healthcare technology stocks are trading... Unlock content with Pro Subscription

3 months ago

-11.3%

AbCellera Biologics shares are trading lower after the company reported worse-than-expected Q4 sales results. Also, Stifel cut its price target on the stock from $12 to $10.

News

3 days ago · businesswire.com

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575.

2 weeks ago · businesswire.com

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause.

3 weeks ago · businesswire.com

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit.

3 weeks ago · businesswire.com

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Positive Preclinical Data on ABCL575 at the SID Annual Meeting 2025.

3 weeks ago · seekingalpha.com

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - President and Chief...

3 weeks ago · zacks.com

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.14 per share a year ago.

1 month ago · businesswire.com

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera presents data showing preclinical efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025.